EU Joint Clinical Assessment Poster Tour

Speaker(s)

Melinda Goodall, MSc PhD, Goodall HTA Consulting, Manchester, Manchester, UK

Posters featured in this tour:

PT25: Comparison of Approval Dates of New Substances between the United States of America (FOOD AND DRUG ADMINISTRATION, FDA) and Europe (EUROPEAN MEDICINES AGENCY, EMA)
PT26: How Aware Are Biotech and Pharmaceutical Companies of the Implementation of the New EU HTA?
PT27: How Much Does TLV Value Rarity? A Review of Reimbursement Decisions on Orphan Drugs in Sweden from 2017 through 2022
PT28: Lost in PICO? a Simulation of the EU HTA Scoping Process
PT29: Predicting PICOs for EU Joint Clinical Assessment: Lessons from PICOs in Relative Effectiveness Assessments (REA) from EUnetHTA Joint Action 3 Project
PT30: Will Health Technology Assessment (HTA) Bodies in Europe Accept Evidence from an External Control Arm to Supplement Evidence from Clinical Trials for Chronic Diseases?

212